Sparks commentary - OSE Immunotherapeutics

Healthcare

Sparks - OSE Immunotherapeutics

More on this equity
OSE-Immunotherapeutics_resized
OSE (PAR: OSE) launches AI immunotherapy partnership
Published by Arron Aatkar, PhD

OSE has signed a strategic partnership with Scienta Lab, aiming to model inflammatory diseases and identify predictive biomarkers of efficacy for immunotherapies. Scienta Lab is a France-based leader in AI-driven precision immunology, and under this agreement, it will be employing its AI-powered multimodal foundation model dedicated to translational immunology research. Ultimately, OSE believes this partnership will support the development of tailored immunotherapies and drive more favourable outcomes for patients with immune-mediated inflammatory conditions.

Cookie Policy Overview
Edison Group

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping us understand which section of the website you find more interesting and useful. See our Cookie Policy for more information.

Strictly necessary and functional

These cookies are used to deliver our website and content. Strictly necessary cookies relate to our hosting environment, and functional cookies are used to facilitate social logins, social sharing and rich-media content embeds.

Advertising

Advertising Cookies collect information about your browsing habits such as the pages you visit and links you follow. These audience insights are used to make our website more relevant.

Performance

Performance Cookies collect anonymous information designed to help us improve the site and respond to the needs of our audiences. We use this information to make our site faster, more relevant and improve the navigation for all users.